Bangladesh, A Poor Country with Success Against Covid-19—Is “the People’s Drug” a Factor?

Bangladesh, A Poor Country with Success Against Covid-19—Is “the People’s Drug” a Factor?

As is occurring in many low-and-middle-income countries (LMICs), TrialSite observes in Bangladesh that while vaccination rates are low, overall problems with COVID-19 have been minimal at least compared to many other nations. This observation was picked up recently by The Daily Telegraph. From November 20, 2021, to December 1, Bangladesh, one of the world’s most populated nations with 165 million, had only one death from COVID-19. This is a significant statistic in a generally poor country with pockets of considerable poverty and overcrowding. Many physicians known to TrialSite, such as Dr. Tarek Alam, were big ivermectin proponents—conducting several studies. One point of view among care providers is that ivermectin influenced this outcome. In Bangladesh, only 22% of the population has been vaccinated against covid, yet the death rate from the virus remains low at just over one percent. Bangladesh has a population of about 165 million but just over 27 thousand deaths from COVID-19. According to an interview with Dr. Alam, last year, ivermectin in Bangladesh combined with Doxycycline and various vitamins and minerals is known as “the People’s Drug.”

Bangladesh experienced ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee